Array BioPharma will soon be entering a pivotal trial for its wholly owned blood cancer drug and investors should know its outlook by the end of 2014, says the company's CEO Ron Squarer. Array is also partnering with AstraZeneca and Novartis on a number of other cancer drugs with trials soon getting underway that could transform the company by year end. Squarer says Array is superior at smaller, faster hematology studies, while partnerships work better for larger projects, and he is not giving away the store when teaming up with the likes of Celgene.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Jim Cramer Has 2 Tips for the Graduating Class of 2018

Jim Cramer Has 2 Tips for the Graduating Class of 2018

Video: Why the Stock Market Is Discounting China Trade Fears for Now

Video: Why the Stock Market Is Discounting China Trade Fears for Now

Did Warren Buffett Make a Bad Mistake by Not Buying General Electric?

Did Warren Buffett Make a Bad Mistake by Not Buying General Electric?

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019